Based on the 2016 International Working Group (IWG) diagnostic criteria for idiopathic pulmonary fibrosis (IPF), outcomes are relatively similar between patients with IPF with pneumonia and patients with an acute IPF exacerbation.
Patients with COPD who have the most severe airflow obstructions according to the GOLD strategy document had more exacerbations than those with less severe obstructions, and were more likely to be treated with both systemic corticosteroids and antibiotics.
Individuals with moderate to very severe COPD and cardiovascular risk factors did not have an increased risk for all-cause mortality or major adverse cardiovascular event occurrence with the use of aclidinium.
Researchers compared lung function improvements within the combination subgroups of high/low eosinophil levels and high/low FEV1 reversibility in patients with moderate to severe asthma treated with omalizumab vs patients who took placebo.
Investigators sought to determine a link between baseline blood eosinophil counts and certain biomarkers and observed that mepolizumab-treated individuals with elevated baseline levels of eosinophil-derived neurotoxin experienced the greatest reduction in exacerbation rates.
The study was designed to examine the prescribing patterns at a large academic teaching center to identify patients who have taken more than one biologic asthma medication, either sequentially or simultaneously, and to analyze the outcomes.
Investigators examined the effectiveness of low-dose beclomethasone/formoterol maintenance and reliever therapy vs beclomethasone/formoterol plus salbutamol to lower the exacerbation rate in patients with moderate to acute asthma.